Aflac (AFL) Stock Forecast & Price Target

Aflac is supported by resilient underlying earnings power, with reported EPS of $1.75 versus consensus of $1.77 and PSC of $1.76, and the miss was driven more by near-term Japan headwinds—an above-target benefit ratio, weaker currency movements, and lower sales—than by any deterioration in the franchise’s core distribution strength. Its outlook is constructive because Japan medical sales remain an important growth engine, momentum in the first half of 2026 exceeded the prior year, the benefits ratio improved and stayed within the full-year guidance range of 60% to 63%, and the company continues to sell multiple products through strong worksite channels while broadening offerings in accident, dental and vision, disability, and long-term-care insurance. Fundamentally, the balance sheet and capital-return story also look stronger after a roughly $4.8 billion investment portfolio restructuring that should add about $50 million of annual pre-tax net investment income and a plan to increase ceding of Japanese liabilities from 10% to about 30%, which freed up approximately $2.5 billion of capital and should enhance financial flexibility over time.

Aflac is facing a negative fundamental outlook because its U.S. business is already showing softer-than-expected net earned premium growth, with management now expecting results to fall below the 3% to 6% guidance range that had already been set to the low end, indicating weaker momentum in a core operating market. Profitability is also under pressure in Japan, where the company missed reported EPS at $1.75 versus consensus of $1.80 and PSC of $1.89, with the miss driven primarily by a pre-tax margin that was less than projected, even as management said earnings emergence was challenged for the second quarter in a row. Although Aflac still highlighted strong distribution and a favorable Japan benefit ratio outlook of 60% to 63%, the need for stronger second-half U.S. sales growth, cautious M&A discipline, and repeated margin and earnings misses suggests execution risk and limited near-term fundamental upside.